FibroBiologics, Inc. received Nasdaq confirmation of compliance with bid price and stockholders' equity requirements for continued listing on The Nasdaq Capital Market, closing prior listing matters.
Key takeaways
Company demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) bid price requirement on April 17, 2026.
Compliance confirmed with $1.00 bid price and $2.5 million stockholders' equity requirements.
All Nasdaq compliance issues resolved, allowing continued trading under FBLG symbol.
Subject to one-year Mandatory Panel Monitor for bid price from April 17, 2026, with no cure period if non-compliant.
One-year monitor for equity rule from March 9, 2026, with direct delisting risk if failed.